Sangamo Plunges After Pfizer Ends Pact for Hemophilia Drug
(Bloomberg) — Sangamo Therapeutics Inc. plummeted in early trading after Pfizer Inc. ended its partnership to develop a new gene therapy to treat hemophilia A. Most Read from Bloomberg Sangamo is considering “all options” to continue developing the drug, including finding a new partner, the company said in a statement Monday. The experimental medicine met … Read more